1.Peptidic HIV fusion inhibitors targeting envelope glycoprotein transmembrane subunit gp41
Shuwen LIU ; Shuguang WU ; Shib JIANG
Chinese Pharmacological Bulletin 2003;0(11):-
HIV envelope glycoprotein transmembrane subunit gp41 plays a major role in the fusion of viral and target cell membranes. The extracellular region of gp41 consists of N-terminal fusion peptide and downstream N- and C-heptad repeat (NHR and CHR) regions. The peptidesderived from the NHR and CHR regions, designated N- and C-peptides, respectively, have potent inhibitory activity on the HIV mediated cell fusion. C-peptide T-20 has just got the approval of U.S. FDA, which became the first success of one new class anti-HIV agents, named HIV-fusion inhibitors. However, a relatively long peptide such as T-20 suffers from several limitations including proteolytic sensitivity, large dosage, therefore it is unable to produced by gene engineering. Alternately, shorter peptidic fusion inhibitors and active peptides suitable for gene engineering are pursued. In the recent years, this kind of peptide modifications are hot spots in HIV research field and contribute a lot to the inhibitory mechanism of N- and C-peptide.
2.Clinical Observation of Shufeng Xuanfei Tang on Treating Cough Variant Asthma Patients
Shuguang JIANG ; Fuyuan FAN ; Sili ZHAO
Chinese Journal of Information on Traditional Chinese Medicine 2006;0(12):-
0.05). Shufeng Xuanfei Tang could decline integral of Chinese medicine syptom markedly after treatment. Shufeng Xuanfei Tang could evidently improve the lung function.Conclusion The effect Shufeng Xuanfei Tang in treating cough variant asthina is sure.
3.Discussion on risk management system of joint-venture medical equipment
Hongwei JIANG ; Chunxia ZHANG ; Shuguang ZHANG
Chinese Medical Equipment Journal 2003;0(11):-
On the view of modern risk management,4 kinds of risks are found out through joint-venture medical equipment actuality investigation.Against these risks,the risk management system of hospital medical equipment is set up to identify and diminish the risks in joint-venture of medical equipment,included management flow optimization,risk management mechanism, risk avoidance and risk analysis.
4.Hepatic artery and portal vein dual perfusion chemotherapy combined with intratumoral injection of lipiodol-ethanol for unresec-table primary hepatic carcinoma
Yong AN ; Ping BIE ; Shuguang WANG ; Zhenghui JIANG
Chinese Journal of General Surgery 2001;10(2):111-114
Objective To study the therapeutic effect of hepatic artery and portal vein dual perfusion chemotherapy (AVPC) combined with intratumoral injection of lipiodol-ethanol (ITILE) for unresectable primary hepatic carcinoma (PHC). Methods 138 pathologically proved and unresectable PHC cases were divided into two groups: Group A (80 cases), treated with AVPC through hypodermic implanted drug delivery pumps. Group B (58 cases), treated with AVPC plus ITILE. Results The secondary resection rate was 2.5% in group A, while 12.1% in group B, (P<0.05); The 0.5, 1, 2 years survival rate in group A was 56.3% 45.0% and 21.2%, in group B 81.0% 61.2% and 39.6% respectively. there were significent difference between two groups in 0.5,1,2 years survival rate respectively (P<0.05); the complication occurrence rate was found no significant difference between two groups (P>0.05). Conclusions The therapeutic effect of AVPC plus ITILE for unresectable PHC is much better than that of AVPC alone.
5.Simvastatin prevents and treats ischemic-type biliary lesion in rats after liver transplantation
Weiwei JIANG ; Shuguang WANG ; Geng CHEN ; Yujun ZHANG
Journal of Third Military Medical University 2002;0(12):-
Objective To explore the preventive effects of simvastatin on ischemic-type biliary lesion (ITBL) after liver transplantation. Methods Totally 90 female SD rats,6 to 8 weeks old,weighing 200 to 250 g,were randomly divided into 3 groups,sham-operation group (n=10),control group (n=40,including 20 donors and 20 receipts),and experimental group (n=40,including 20 donors and 20 receipts). Rat liver transplantation was established by reconstructing hepatic artery. The rats of experimental group were fed with a normal chow containing 0.1% simvastatin for 1 week before operation and for 2 weeks after operation. The donor liver was stored in the University of Wisconsin solution at 4 ℃ for 12 h followed by transplantation. The animals were killed in 2 weeks after operation and the bile,bile duct and liver tissue were taken. High performance liquid chromatography (HPLC) was used to detect the concentrations of bile salts. Biochemistry,histopathology,immunohistochemistry and RT-PCR were employed to measure the level of phospholipids C,observe the pathological changes of liver,detect the protein and mRNA expressions of phospholipid transfer protein (Mdr2 P-glycoprotein). Results The biliary phospholipid composition of rats in the experimental group (3.874 8?1.414 8 mg/dl) was significantly increased,compared with the sham-operation group (1.982 1?0.413 5 mg/dl) and the control group (1.428 5?0.538 7 mg/dl) (P
6.VEGF enhances serum levels of HGF and IL-6 in rats following 50 percent partial liver transplantation
Xiaoling DONG ; Shuguang WANG ; Yujun ZHANG ; Yan JIANG
Journal of Third Military Medical University 2003;0(11):-
Objective To determine the effects of exogenous VEGF on the serum levels of HGF and IL-6 in rats following partial liver transplantation.Methods Totally 180 SD rats were subjected to 50 percent partial liver transplantation,then each 60 rats were treated either with VEGF,anti-VEGF or normal saline.HGF,IL-6 and hepatic biochemical markers were assessed at 0,12,24,72,168 h after operation.Results In the VEGF group,the serum levels of HGF and IL-6 were significantly increased as compared with those of anti-VEGF group or control group.Blockage of endogenous VEGF led to a marked increase of ALT and AST.Conclusion VEGF can markedly increase the secretion of HGF and IL-6,which may be related to its enhancing liver regeneration and improving liver function.
7.Risk factors of upper gastrointestinal injury induced by non-steroidal anti-inflammatory drugs
Guoyong RUAN ; Yingjie JIANG ; Wei SHI ; Aixia LIANG ; Shuguang LI
Chinese Journal of Postgraduates of Medicine 2013;(7):37-40
Objective To investigate the risk factors of upper gastrointestinal injury induced by non-steroidal anti-inflammatory drugs (NSAIDs).Methods A total of 1032 patients which used NSAIDs was selected.Patients were divided into two groups based on the condition of dyspepsia,peptic ulcer or upper gastrointestinal bleeding:the adverse drug reaction group (331 cases) and the control group (701 cases).Data of two groups on clinical presentation,laboratory test,medication and treatment were analyzed.Risk factors for the adverse drug reaction were identified by multivariable Logistic regression.Results The two groups had significant difference in age > 65 years old,Helicobacter pylori (Hp) infection,ulcer history,drug overdose,combination with glucocorticoid,addicted to tobacco and alcohol history,non-specific inhibitor of cyclooxygenase(COX)-2,combination with anticoagulant,concomitant chronic cardiopulmonary disease (P < 0.05).Logistic regression analysis by backward elimination method revealed that following variables retained,such as combination with glucocorticoid (OR =3.104,95% CI 1.936-4.695),Hp infection (OR =2.768,95% CI 2.047-3.742),drug overdose (OR =2.411,95% CI 1.683-3.453),ulcer history (OR =1.781,95% CI 1.278-2.480),age > 65 years old (OR =1.659,95% CI 1.237-2.225),non-specific inhibitor of COX-2 (OR =1.470,95% CI 1.103-2.133),addicted to tobacco and alcohol history (OR =1.459,95% CI 1.032-2.064),concomitant chronic cardiopulmonary disease (OR =1.357,95% CI 1.008-2.143),P<0.05.Conclusion Combination with glucocorticoid,Hp infection,drug overdose,ulcer history,age > 65 years old,non-specific inhibitor of COX-2,addicted to tobacco and alcohol history,concomitant chronic cardiopulmonary disease are risk factors of upper gastrointestinal injury induced bv NSAIDs.
8.Discussion on pattern of evidence-based medical equipment quality management
Hongwei JIANG ; Shuguang ZHANG ; Chunxia ZHANG ; Yuxin ZHAO ; Yuan LI
Chinese Medical Equipment Journal 2003;0(11):-
The improvement of quality management for medical equipment is an important part in overall quality management for modern hospital under the new circumstance of medical reform.The principles and approaches of evidence-based medicine were applied to quality management for medical equipment.In the view of generalized quality management,the core thoughts and basic framework of evidence-based quality management for medical equipment were put forward.The foundation of evidence-based management system was discussed including organization structure,PDCA quality management cycle,quality evidence procedure and overall quality-evaluating index system.
9.Survivin-siRNA inhibits proliferation of lung cancer A549 cells and enhances their chemosensitity to cisplatin
Shuguang ZHANG ; Xiaofan LIU ; Jiang DU ; Wenya LI ; Lin ZHANG
Chinese Journal of Cancer Biotherapy 2009;16(6):583-587
Objective:To investigate the effect of survivin-siRNA plasmid on survivin expression in human lung cancer cell line A549, and to observe its effect on the apoptosis, proliferation, and chemosensitivity of A549 cells. Methods: pSilencer-survivin-siRNA (survivin-siRNA) plasmid was constructed using pSilencer-U6 plasmid and was transfected into A549 cells. Expression of survivin mRNA and protein was examined by RT-PCR and Western blotting analysis, respec-tively. Apoptosis and proliferation of A549 cells were examined by DAPI staining and MTT, respectively. Results: Sur-vivin-siRNA plasmid was successfully constructed, and it significantly inhibited survivin mRNA and protein expression in A549 cells. Survivin-siRNA transfection induced apoptosis, inhibited proliferation and increased chemosensitivity of A549 cells to cisplatin. Conclusion: pSilencer-survivin-siRNA can silence survivin expression in A549 cells and subsequently inhibit proliferation, promote apoptosis, and enhance chemosensitivity of A549 cells to cisplatin. Survivin may serve as a potential target for gene therapy of lung cancer.
10.LOXL2 and its relation with epithelial-mesenchymal transition cholangiocarcinoma
Yinghong GAO ; Tianyu LI ; Zhanfeng GAO ; Weiwei JIANG ; Shuguang WANG
Chinese Journal of General Surgery 2008;23(10):784-787
Objective To investigate the expression of LOXL2 protein (lysyl oxidase like-2 protein) and epithelial-mesenchymal transition (EMT) related markers in cholangiocarcinoma tissues and its relation with the malignant features. Methods The expression of LOXL2、E-cadherin and Vimentin protein in 48 cases of cholangiocarcinoma tissues was detected by immunohistochemistry and compared with the clinicopathological data of cholangiocarcinoma. Results The positive expression rate in cholangiocarcinoma was 71% ( 34/48 ) for LOXL2 and 46% ( 22/48 ) for Vimentin, the absent expression rate was 52% (25/48) for E-cadherin. The positive expression rate of LOXL2 was significantly associated with the absent expression of epithelium markers E-cadherin ( r = 0. 394, P < 0. 05 ) and the positive expression of fibroblast markers Vimentin ( r = 0. 406, P < 0. 05 ). There was no correlation between the expression of LOXL2 and patients gender, age, and cancer differentiation, but a significant correlation with tumor metastasis was found ( P < 0. 05 ). Conclusions LOXL2 protein overexpression in cholangiocarcinoma may accelerate invasion of cholangiocarcinoma through induced EMT.